Translational Oncology

雜志介紹

Translational Oncology雜志介紹

《Translational Oncology》是一本以English為主的開放獲取國際優秀期刊，中文名稱轉化腫瘤學，本刊主要出版、報道醫學-ONCOLOGY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為4.5，最新CiteScore 指數為8.4。

本刊近期中國學者發表的論文主要有：

• Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progression

  Author: Xu, Yingqi; Xu, Jianlin; Qiao, Rong; Zhong, Hua; Xia, Jinjing; Zhong, Runbo

• The roles of Linc-ROR in the regulation of cancer stem cells

  Author: Wen, Xiaoling; Wu, Yingying; Lou, Yanhui; Xia, Yufang; Yu, Xiao

• Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation

  Author: Jin, Xin; Ma, Xiaoting; Zhao, Dong; Yang, Lin; Ma, Nan

• circ-ZEB1 regulates epithelial-mesenchymal transition and chemotherapy resistance of colorectal cancer through acting on miR-200c-5p

  Author: Chen, Hongyu; Zhang, Jianwei; Yang, Lei; Li, Yansen; Wang, Zhenjun; Ye, Chunxiang

英文介紹

Translational Oncology雜志英文介紹

Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.